Covered recipient · General Payments record
PAUL R SIEBER
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$68,752.86
180 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,310.00 | 11 |
| Consulting Fee | $24,290.00 | 8 |
| Travel and Lodging | $11,103.14 | 37 |
| Food and Beverage | $3,881.24 | 121 |
| Education | $168.48 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $19,646.14 | 38 |
| Astellas Pharma US Inc | $12,057.84 | 27 |
| PFIZER INC. | $11,374.45 | 24 |
| Astellas Pharma Global Development | $9,424.63 | 8 |
| Ferring Pharmaceuticals Inc. | $6,296.79 | 17 |
| Janssen Biotech, Inc. | $4,368.42 | 17 |
| Clovis Oncology, Inc. | $2,249.95 | 5 |
| Boston Scientific Corporation | $1,441.90 | 6 |
| Merck Sharp & Dohme Corporation | $1,058.96 | 10 |
| Sun Pharmaceutical Industries Inc. | $257.27 | 6 |
| Dendreon Pharmaceuticals LLC | $249.74 | 7 |
| AbbVie, Inc. | $109.77 | 6 |
| COMSORT, Inc | $100.00 | 1 |
| TOLMAR Pharmaceuticals, Inc. | $38.35 | 2 |
| TherapeuticsMD, Inc. | $16.67 | 1 |
| Foundation Medicine, Inc. | $16.44 | 1 |
| Endo Pharmaceuticals Inc. | $13.07 | 1 |
| Coloplast Corp | $12.58 | 1 |
| EMD Serono, Inc. | $11.35 | 1 |
| Janssen Pharmaceuticals, Inc | $8.54 | 1 |
Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAUL R SIEBER
NPI 1851375026 · CMS profile ID 174335
Allopathic & Osteopathic Physicians / Urology
LANCASTER, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PAUL R SIEBER, NPI 1851375026, CMS profile ID 174335, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–180 of 180 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1851375026?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
180 matching records · $68,752.86 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–180 of 180.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma Global Development | $263.94 | 03/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641930277 | CMS |
| Astellas Pharma Global Development | $177.11 | 03/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641930279 | CMS |
| Astellas Pharma Global Development | $270.70 | 03/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641930281 | CMS |
| PFIZER INC. | $9.76 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671911749 | CMS |
| PFIZER INC. | $14.07 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671874171 | CMS |
| Dendreon Pharmaceuticals LLC | $25.20 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703770361 | CMS |
| Ferring Pharmaceuticals Inc. | $13.30 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655218299 | CMS |
| Astellas Pharma US Inc | $9.58 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655761867 | CMS |
| PFIZER INC. | $89.99 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672598741 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $110.05 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628452407 | CMS |
| Janssen Biotech, Inc. | $102.79 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658716364 | CMS |
| Janssen Biotech, Inc. | $6.14 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658716360 | CMS |
| Astellas Pharma US Inc | $15.54 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655761865 | CMS |
| AbbVie, Inc. | $23.83 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648145261 | CMS |
| Dendreon Pharmaceuticals LLC | $22.50 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703770359 | CMS |
| Ferring Pharmaceuticals Inc. | $15.30 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655218297 | CMS |
| Janssen Biotech, Inc. | $12.01 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658716355 | CMS |
| AbbVie, Inc. | $12.77 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648145255 | CMS |
| Janssen Biotech, Inc. | $5.66 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658716351 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $7.62 | 01/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628449653 | CMS |
| Janssen Biotech, Inc. | $68.55 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658716345 | CMS |
| Merck Sharp & Dohme Corporation | $35.00 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613615 | CMS |
| Merck Sharp & Dohme Corporation | $30.98 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613961 | CMS |
| Merck Sharp & Dohme Corporation | $33.00 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613965 | CMS |
| Merck Sharp & Dohme Corporation | $9.60 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695614083 | CMS |
| Merck Sharp & Dohme Corporation | $74.22 | 01/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613619 | CMS |
| Merck Sharp & Dohme Corporation | $213.57 | 01/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613681 | CMS |
| Merck Sharp & Dohme Corporation | $22.82 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613959 | CMS |
| Merck Sharp & Dohme Corporation | $62.63 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695614079 | CMS |
| Merck Sharp & Dohme Corporation | $552.51 | 01/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695613967 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,223.19 | 10 |
| PY2025 | Principal investigator | $1,566,575.84 | 119 |
| PY2024 | Recipient | $5,080.00 | 3 |
| PY2024 | Principal investigator | $2,395,471.29 | 191 |
| PY2023 | Recipient | $1,650.00 | 5 |
| PY2023 | Principal investigator | $1,577,803.80 | 257 |
| PY2022 | Principal investigator | $1,379,025.92 | 340 |
| PY2021 | Recipient | $7,000.00 | 1 |
| PY2021 | Principal investigator | $1,381,716.11 | 213 |
| PY2020 | Principal investigator | $1,840,393.81 | 304 |
| PY2019 | Recipient | $63.72 | 1 |
| PY2019 | Principal investigator | $1,818,552.15 | 321 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
129 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Lancaster Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926515 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $25,308.02 | 12/29/2025 | Non-covered Recipient Entity Lancaster Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,087.00 | 12/25/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175379319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,703.00 | 12/22/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342264 |
| Principal investigator 1 | Janssen Research & Development, LLC | $880.00 | 12/18/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342234 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,955.00 | 12/01/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175379276 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,016.00 | 11/28/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175379338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 11/27/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175379240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 11/27/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175379256 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 11/14/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892616 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,600.00 | 11/14/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892620 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $800.00 | 11/14/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892623 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/10/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725090 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/08/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727231 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $833.60 | 11/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654857 |
| Principal investigator 1 | Janssen Research & Development, LLC | $886.00 | 11/03/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175379284 |
| Recipient | PFIZER INC. | $330.00 | 11/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727783 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 10/30/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726634 |
| Principal investigator 1 | PFIZER INC. | $92,415.77 | 10/29/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727393 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,000.00 | 10/24/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175379346 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 10/17/2025 | Non-covered Recipient Entity Lancaster Uro | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175265689 |
| Principal investigator 1 | PFIZER INC. | $6,230.62 | 10/14/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228737191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $442.00 | 10/13/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175342165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,703.00 | 10/13/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342181 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $881.26 | 10/10/2025 | Non-covered Recipient Entity Keystone Urology Specialists | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419857 |
| Principal investigator 1 | PFIZER INC. | $21,499.00 | 10/08/2025 | Non-covered Recipient Entity The Centers for Advanced Urology LLP dba Keystone Urology Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228741837 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892479 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $50.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892483 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,600.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892486 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,600.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892489 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892492 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $50.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892496 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $50.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892499 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $500.00 | 09/26/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,699.00 | 09/26/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379296 |
| Principal investigator 1 | Janssen Research & Development, LLC | $706.00 | 09/26/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379304 |
| Principal investigator 1 | Janssen Research & Development, LLC | $880.00 | 09/08/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342254 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $521.80 | 08/31/2025 | Non-covered Recipient Entity Lancaster Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926559 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/21/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726484 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/20/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726674 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 08/18/2025 | Non-covered Recipient Entity Lancaster Uro | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175265706 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/11/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727557 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/10/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $423.00 | 08/07/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379264 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/02/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727067 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 08/01/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641711 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,667.20 | 08/01/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641787 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 08/01/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641836 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/31/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725990 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,621.00 | 07/28/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379353 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 07/17/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342173 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $833.60 | 07/09/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640400 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,116.00 | 07/03/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $706.00 | 07/03/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379327 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,674.00 | 06/30/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379249 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/24/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891672 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/24/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892234 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,703.00 | 06/16/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342202 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $453.13 | 06/12/2025 | Non-covered Recipient Entity Keystone Urology Specialists | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225402505 |
| Recipient | Dendreon Pharmaceuticals LLC | $25.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891649 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891653 |
| Recipient | Dendreon Pharmaceuticals LLC | $322.73 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891656 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,800.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891660 |
| Recipient | Dendreon Pharmaceuticals LLC | $30.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891664 |
| Recipient | Dendreon Pharmaceuticals LLC | $800.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891669 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $16,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247891953 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $13,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247891957 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $50.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892102 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892106 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892112 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $3,600.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892119 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $150.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892123 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $800.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892126 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $19,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892192 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $13,000.00 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892197 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $211.99 | 06/05/2025 | Non-covered Recipient Entity CHESAPEAKE UROLOGY ASSOCIATES LLC | ProvONE | No dispute reported | 06/30/2026 | 1247892201 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/02/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751297 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/01/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753921 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/01/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $94.00 | 05/19/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342227 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,028.00 | 05/19/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,699.00 | 05/19/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379231 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 05/16/2025 | Non-covered Recipient Entity Lancaster Uro | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175265682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $423.00 | 05/16/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379360 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 05/13/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752414 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770908 |
| Principal investigator 1 | PFIZER INC. | $92,412.24 | 05/12/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752828 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 05/12/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754361 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $60.00 | 05/07/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634162 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $833.60 | 05/07/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634173 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,856.00 | 04/25/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LL P | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175379310 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $60.00 | 04/09/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632579 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,394.40 | 04/09/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632601 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,500.00 | 04/09/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE UROLOGY SPECIAL | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176632847 |
| Principal investigator 1 | Janssen Research & Development, LLC | $221.00 | 03/31/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175342272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $880.00 | 03/31/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342279 |
| Principal investigator 1 | MEDIVATION LLC. | $120.00 | 03/25/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776848 |
| Principal investigator 1 | MEDIVATION LLC. | $150.00 | 03/25/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778259 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 03/13/2025 | Non-covered Recipient Entity Lancaster Uro | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175265698 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,699.00 | 03/10/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175342194 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,703.00 | 03/10/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342285 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,400.00 | 03/05/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | No dispute reported | 06/30/2026 | 1185543945 |
| Principal investigator 1 | PFIZER INC. | $15,402.04 | 03/04/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752410 |
| Principal investigator 1 | MEDIVATION LLC. | $222.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228719957 |
| Principal investigator 1 | MEDIVATION LLC. | $222.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724696 |
| Principal investigator 1 | MEDIVATION LLC. | $222.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774687 |
| Principal investigator 1 | MEDIVATION LLC. | $222.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774691 |
| Principal investigator 1 | MEDIVATION LLC. | $222.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775378 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776395 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778050 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228784925 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 03/03/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786409 |
| Principal investigator 1 | PFIZER INC. | $15,402.04 | 03/03/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754027 |
| Principal investigator 1 | PFIZER INC. | $15,402.63 | 03/03/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,709.00 | 02/28/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175342217 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/12/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752406 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 02/11/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752994 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 02/11/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754880 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,400.00 | 02/06/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234183427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $880.00 | 02/03/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175342186 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $503.13 | 01/30/2025 | Non-covered Recipient Entity Keystone Urology Specialists | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225405204 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 01/28/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776078 |
| Principal investigator 1 | MEDIVATION LLC. | $859.20 | 01/28/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777133 |
| Principal investigator 1 | MEDIVATION LLC. | $1,086.00 | 01/28/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,648.00 | 01/27/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175342210 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,808.00 | 01/27/2025 | Non-covered Recipient Entity KEYSTONE UROLOGY SPECIALISTS | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175342245 |
| Principal investigator 1 | MEDIVATION LLC. | $1,008.00 | 01/02/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777779 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/02/2025 | Non-covered Recipient Entity Lancaster Urology | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752823 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2021 | Amount invested | $328.74 | 1 |
| PY2021 | Value of interest | $0.00 | 1 |
| PY2020 | Amount invested | $328.74 | 1 |
| PY2020 | Value of interest | $0.00 | 1 |
| PY2019 | Amount invested | $328.74 | 1 |
| PY2019 | Value of interest | $0.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
3 records · PY2019–2021
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2021 | Innovative Medical Technologies, LLC | $328.74 | $0.00 | Membership Units in Limited Liability Company-Ownership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 834570393 |
| PY2020 | Innovative Medical Technologies, LLC | $328.74 | $0.00 | Membership Units in Limited Liability Company-Ownership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 748292283 |
| PY2019 | Innovative Medical Technologies, LLC | $328.74 | $0.00 | Membership Units in Limited Liability Company-Ownership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 676681615 |